⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 33 in last 7 days 🍎 Food: 79 in last 7 days 🧸 Products: 98 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 32 minutes ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 33 in last 7 days 🍎 Food: 79 in last 7 days 🧸 Products: 98 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 32 minutes ago
🛡️ EUSW
💊 Medicines 🍎 Food 🧸 Products 🔎 Search
📊 Data
🏷 Brands 🌍 Countries ℹ️ About ✉ Unsubscribe
🇬🇧
🇬🇧 English 🇳🇱 Nederlands 🇫🇷 Français 🇩🇪 Deutsch 🇪🇸 Español 🇮🇹 Italiano 🇵🇹 Português 🇵🇱 Polski 🇸🇪 Svenska 🇷🇴 Română 🇨🇿 Čeština 🇫🇮 Suomi 🇩🇰 Dansk
💊 Medicine AT May 29, 2026

Febuxostat Sandoz 120 mg - Filmtabletten 120 mg (Filmtablette)

📷 EU Safety Watch placeholder
Febuxostat Sandoz 120 mg - Filmtabletten 120 mg (Filmtablette)
📷 EU Safety Watch placeholder
Febuxostat Sandoz 120 mg film-coated tablets are subject to a parallel export ban. The affected pack sizes are the 30-tablet box, which has been unavailable since 29 May 2026, and the 14-tablet box, which remains available.
⚠️
Shortage ongoing
FEBUXOSTAT HEMIHYDRAT is currently in short supply in AT.
📈 Timeline
12 days active so far
May 30, 2026 June 10, 2026

What is this? Febuxostat is a medicine used to lower high uric acid in gout. It comes as 120 mg tablets.

What's happening? Some packs of 30 tablets are not available due to making problems. Smaller packs of 14 tablets are still in stock.

Does this affect me? If you take this medicine, you may need a different pack size or brand.

What should I do? Ask your pharmacist or doctor for advice before changing how you take your medicine.

🤖 This plain-language summary is automatically generated from the official agency notice using AI. It is for general information only — not medical advice. For decisions about your health, always consult a pharmacist or doctor and read the official source linked below.

🔬 Medical / technical details (for professionals)
Active substance(s)
FEBUXOSTAT HEMIHYDRAT
Agency-published detail

🚫 Parallel export ban active · ATC: M04AA03 · Reason: Kapazitätsengpässe bei der Herstellung · Marketing authorisation holder: Sandoz GmbH, Biochemiestraße 10, 6250 Kundl, Österreich · Affected packs: 30 Stück Schachtel, Blisterpackung [Nicht verfügbar, since 2026-05-29] · 14 Stück Schachtel, Blisterpackung [verfügbar]

First published
May 29, 2026
Last refreshed by us
6 hours ago
Severity (as classified)
High
Official source
https://medikamente.basg.gv.at/en/medicine-shortage

All information on this page comes from the official agency notice. We translate and summarise it; we don't add or edit facts.

Related alerts

High AT 1 month ago

Febuxostat Sandoz 80 mg - Filmtabletten 80 mg (Filmtablette)

Febuxostat Sandoz 80 mg film-coated tablets are subject to a parallel export ban.

❓ Frequently asked questions

▸ What is this medicine shortage alert about?
Febuxostat Sandoz 120 mg - Filmtabletten 120 mg (Filmtablette). Febuxostat Sandoz 120 mg film-coated tablets are subject to a parallel export ban. The affected pack sizes are the 30-tablet box, which has been unavailable since 29 May 2026, and the 14-tablet box, which remains available.
▸ When was this alert issued?
This alert was issued on May 29, 2026 by BASG (Austria).
▸ Which countries are affected?
The alert applies to Austria.
▸ How serious is this alert?
Serious risk. A serious risk means the product or medicine can cause significant harm. Treat the alert as urgent.
▸ What should I do?
If you take this medicine, contact your pharmacist or prescribing doctor. They can advise on alternative products or substitutes. Do not stop taking prescription medicine without medical advice.
▸ Where can I find the official notice?
The full official notice is published on medikamente.basg.gv.at.

💬 Discussion

Share your experience or ask a question. Real names and email are optional but moderation friendly.

No comments yet — be the first.

We email a confirmation link. Your address stays private.

⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.